Janux Therapeutics
JANX
64 hedge funds and large institutions have $360M invested in Janux Therapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 7 closing their positions.
500% more call options, than puts
Call options by funds: $60K | Put options by funds: $10K
145% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 11
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
12% more funds holding
Funds holding: 57 → 64 (+7)
2% more capital invested
Capital invested by funds: $354M → $360M (+$5.56M)
3.54% less ownership
Funds ownership: 76.1% → 72.56% (-3.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.78M |
| 2 |
BlackRock
New York
|
+$1.06M |
| 3 |
Cerity Partners
New York
|
+$527K |
| 4 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$509K |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$446K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.69M |
| 3 |
Janus Henderson Group
London,
|
-$1.18M |
| 4 |
JP Morgan Chase
New York
|
-$1.13M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.08M |
JANX Hedge Fund Activity: Q4 2023 in Review
64 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q4 2023, worth a combined $360M — up 1.6% from $354M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new JANX positions and 7 closed out — a net gain of 7 holders — while 27 added to existing stakes and 11 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $1.78M. The largest seller was Fidelity Investments, cutting an estimated $14.5M.
- 64 institutional investors held Janux Therapeutics (JANX) as of Q4 2023, up from 57 in Q3 2023.
- Funds reported $360M of Janux Therapeutics stock for Q4 2023, up 1.6% quarter-over-quarter.
- 14 funds opened new Janux Therapeutics positions in Q4 2023 and 7 closed out, a net change of +7 holders.
- The largest Janux Therapeutics buyer in Q4 2023 was Adage Capital Partners, an estimated $1.78M added.
- The largest Janux Therapeutics seller in Q4 2023 was Fidelity Investments, an estimated $14.5M sold.
Based on aggregated 13F filings for Q4 2023.